A retrospective study on molecular epidemiology trends of carbapenem resistant *Enterobacteriaceae* in a teaching hospital in Malaysia

Zhi Xian Kong¹, Rina N. Karunakaran¹, Kartini Abdul Jabar¹, Sasheela Ponnampalavanar², Chun Wie Chong³ and Cindy Shuan Ju Teh¹

¹ Department of Medical Microbiology, University of Malaya, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
² Department of Medicine, University of Malaya, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
³ School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia

**ABSTRACT**

**Background:** Carbapenem resistant *Enterobacteriaceae* (CRE) has rapidly disseminated worldwide and has become a global threat to the healthcare system due to its resistance towards “last line” antibiotics. This study aimed to investigate the prevalence of CRE and the resistance mechanism as well as the risk factors associated with in-hospital mortality.

**Methods:** A total of 168 CRE strains isolated from a tertiary teaching hospital from 2014–2015 were included in this study. The presence of carbapenemase genes and minimum inhibitory concentration of imipenem, meropenem and colistin were investigated. All carbapenem-resistant *Klebsiella pneumoniae* (*K. pneumoniae*) strains were characterised by PFGE. The risk factors of patients infected by CRE associated with in-hospital mortality were determined statistically.

**Results:** The predominant CRE species isolated was *K. pneumoniae*. The carbapenemases detected were *bla*OXA-48, *bla*OXA-232, *bla*VIM and *bla*NDM of which *bla*OXA-48 was the predominant carbapenemase detected among 168 CRE strains. A total of 40 CRE strains harboured two different carbapenemase genes. A total of seven clusters and 48 pulsotypes were identified among 140 CRKp strains. A predominant pulsotype responsible for the transmission from 2014 to 2015 was identified. Univariate statistical analysis identified that the period between CRE isolation and start of appropriate therapy of more than 3 days was statistically associated with in-hospital mortality.

**INTRODUCTION**

Carbapenem resistance is a recognised worldwide threat by the World Health Organisation (WHO). One of the major causes for the emergence of carbapenem resistant
pathogens is the overuse of carbapenems in the management of infections caused by extended-spectrum beta-lactamases (ESBLs)-expressing Enterobacteriaceae (Nordmann, Dortet & Poirel, 2012; Slama, 2008; Rahal, 2008). Indeed, given that carbapenem is recommended for the treatment of ESBL infections (Paterson et al., 2004), a steady rise in carbapenem resistance had been recorded in Malaysia with the increasing use of the antibiotics (Institute for Medical Research, 2020).

Carbapenem-resistant Klebsiella pneumoniae (CRKp) has persisted and has been gradually rising since its first discovery. For instance, in southeastern United States, a five-fold increase in CRKp infections were recorded from 2008 to 2012 (Thaden et al., 2014). Although carbapenem resistance data is limited, particularly in Southeast Asia, a meta-analysis revealed high estimated carbapenem resistance among Klebsiella spp. in Indonesia, the Philippines, Thailand and Vietnam and among E. coli in Indonesia and Myanmar (Malchione et al., 2019). Among the recorded carbapenem resistant Enterobacteriaceae (CRE), K. pneumoniae is the most prevalent species in Malaysia (Institute for Medical Research, 2020; Zaidah et al., 2017).

The widespread distribution of CRKp over different geographical regions is commonly associated with high-risk clones and the acquisition of carbapenemase genes encoded in mobile genetic elements (David et al., 2019; Pitout, Nordmann & Poirel, 2015). In a parallel survey by the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE), a 1.3% increase in population-weighted mean percentage in carbapenem-resistant K. pneumoniae and Escherichia coli (E. coli) was recorded in EU member states from 2011–2014 (Xu et al., 2015; Thaden et al., 2014; European Centre for Disease Prevention and Control, 2020). In Malaysia, the reported carbapenemases that produced by Enterobacteriaceae are blaNDM, blaIMP, blaOXA-48, blaOXA-181 and blaKPC (Hamzan et al., 2015; Wang et al., 2016; Lau et al., 2020).

CRE is commonly associated with nosocomial infection. A previous study had identified several factors associated with CRE acquisition such as previous overseas hospitalisation, ICU admission and comorbidities (cardiovascular disease and hematology condition) (Ling et al., 2015). Furthermore, studies had also revealed that usage of mechanical ventilation, presence of central venous catheter and receiving immunosuppressants were associated with mortality (Low et al., 2017; Wang et al., 2016). Understanding the transmission of CRE as well as their resistance mechanism is essential to inform the infection control strategy for containing the spread of CRE. In this study, we investigated the epidemiology of CRE (from 2014 to 2015) in a teaching hospital in Klang Valley, Malaysia. The risk factors associated with mortality among the patients infected or colonised with CRE was also examined.

**MATERIALS AND METHODS**

**Ethics statement**

The medical ethics approval for clinical strains collection and clinical/patients’ data access was obtained from University of Malaya Medical Centre (UMMC) Medical Research Ethics Committee in 2015 (MECID.NO: 20154-1249). In this retrospective study, the informed consent from patient is not required.
Hospital setting and bacterial collection

Strain collection was conducted in UMMC, a tertiary teaching and public hospital with 1,617 beds located in Klang Valley, Malaysia. The *Enterobacteriaceae* clinical cultures that had been identified as carbapenem resistant in the Medical Microbiology Diagnostic Laboratory (MMDL) of UMMC were retrospectively collected and included in the study. All the included strains were the first CRE isolated and stocked from the patients’ samples between 1st of January of 2014 to 31st of December of 2015. When different sample types received on the same day from a patient had grown CRE, only the first strain per patient which was stocked was included.

Detection of carbapenemase genes among CRE strains

Crude DNA from the CRE strains was prepared using direct boiling method as mentioned by Lim, Teh & Thong (2013). The presence of carbapenemase genes such as *bla*KPC, *bla*NDM, *bla*VIM, *bla*IMP, *bla*OXA among the CRE strains were identified by polymerase chain reaction (PCR) as previously described by Naas et al. (2008), Nordmann, Naas & Poirel (2011), Poirel et al. (2011), and Poirel et al. (2004) respectively. The amplicons were analysed on 1.0% agarose gel.

Evaluation of antibiotic susceptibility

The MIC value of imipenem, meropenem and colistin among the CRE strains were determined through broth microdilution method according to the Clinical and Laboratory Standard Institute (CLSI) guidelines (Clinical and Laboratory Standards Institute (CLSI), 2021). The MIC breakpoints from the CLSI guidelines was used for imipenem and meropenem (Clinical and Laboratory Standards Institute (CLSI), 2021) while European Committee on Antimicrobial Susceptibility Testing (EUCAST) was used to interpret for the susceptibility of colistin (The European Committee on Antimicrobial Susceptibility Testing (EUCAST), 2021). According to CLSI guidelines, the MIC breakpoints of imipenem and meropenem for susceptible, intermediate, and resistant are ≤1, 2, ≥4 µg/mL respectively. Whilst, according to EUCAST, the MIC breakpoints of colistin for susceptible and resistant are ≤2 and >2 µg/mL respectively. The antibiotic susceptibility of ertapenem was obtained from Medical Microbiology Diagnostic Laboratory (MMDL) of UMMC where the disc diffusion test was carried out. The results were re-interpreted according to CLSI guidelines year of 2021 (Clinical and Laboratory Standards Institute (CLSI), 2021).

Clinical data collection

The clinical details at the time of the CRE isolation were obtained from the patient’s case notes. These details are clearly characterised: (1) A CRE colonisation is defined as the isolation of the microorganism from any non-sterile body sites (usually rectum or perianal area, and respiratory tract/oral cavity, vagina, skin and urine) in the absence of clinical findings of infection (Girmenia et al., 2015). (2) Hospital-acquired infection is defined as infection with positive culture obtained from patients already hospitalised for 48 h or longer (Friedman et al., 2002). Healthcare-associated infection was defined as infection with positive culture obtained at admission or within 48 h or from someone with history of
previous hospitalisation or medical procedures (Friedman et al., 2002). (3) Empirical antibiotics is defined as antibiotic that is given to the patients with sign and symptoms of infection before the identification of organisms and susceptibility data were available. (4) Targeted antibiotic is defined as antibiotic that is given to the patients after the culture and susceptibility data is available. (5) Invasive device is defined as a medical device that is introduced into the body, either through a break in the skin or body orifice. This includes central venous line, peripheral line, peripherally inserted central catheter, nasogastric tube, catheter bladder drainage, internal jugular catheter and external ventricular drain. (6) An invasive procedure is defined as one where access to the body is gained via an incision, percutaneous puncture, where instrumentation is used in addition to the puncture needle, or instrumentation via a natural orifice. Invasive procedures include, but are not limited to, endoscopes, catheters, scalpels, scissors, devices, and tubes (Cousins, Blencowe & Blazeby, 2019). (7) Underlying disorder is defined as an acute or chronic comorbidity or condition not related to sepsis that alters short- and/or long-term survival of infectious diseases (Dhainaut et al., 2005). (8) Length of hospitalisation is defined as length of inpatient care, which calculated from the day of admission to the day of discharge. (9) Appropriate therapy is defined as the use of antimicrobial agents with in-vitro activity against the etiologic pathogens (American Thoracic Society, 2005).

**Molecular detection of porin genes in Klebsiella spp.**
The presence of porin associated genes such as ompK35, ompK36 and ompK37 among the Klebsiella spp. were determined by PCR as previously described by Kaczmarek et al. (2006). The PCR product was analysed on 1.0% agarose gel.

**Clonal relatedness of carbapenem resistant Klebsiella pneumoniae**
The clonal relationship between CRKp strains were investigated using pulse-field gel electrophoresis (PFGE). Plug consisted of extracted whole genomic DNA were digested by XbaI restriction enzyme as previously described by Low et al. (2017). The banding patterns produced were analysed using BioNumerics software (AppliedMaths, Philadelphia, PA, USA). Unweighted Pair Group Method with Arithmetic (UPGMA) were utilised for the cluster analysis with Dice correlation coefficient and 1.5% of tolerance and 1.0% optimisation. The clustering analysis was performed based on the similarity value of ≥80%.

**Statistical analysis**
The risk factors associated with mortality were deduced statistically using statistical software SPSS 2.0. All continuous variables were expressed as mean ± standard deviation. Nominal variables were evaluated by Fishers’ exact test or chi-square as appropriate while continuous variables were evaluated by student t test or Mann Whitney U test based on the data normality. The analysis was deemed as statistically significant if the P value were less than 0.05.
RESULTS

Identification of CRE samples in patients' samples

A total of 34 (from 34 patients) and 134 (from 134 patients) CRE strains were retrospectively collected from 2014 and 2015, respectively. *K. pneumoniae* was the dominant species isolated in both 2014 and 2015, contributed to 73.5% (*n* = 25) and 85.8% (*n* = 115) of the total CRE strains in 2014 and 2015, respectively (Table 1). In 2014, a small number of *Enterobacter cloacae* (*n* = 4, 11.8%), *Escherichia coli* (*n* = 1, 2.9%), *Citrobacter freundii* (*n* = 2, 5.9%) and *Klebsiella oxytoca* (*n* = 2, 5.9%) were collected. In 2015, the non-*Klebsiella* species isolated were *Escherichia coli* (*n* = 11, 8.3%), *Citrobacter freundii* (*n* = 2, 1.5%), *Enterobacter cloacae* (*n* = 2, 1.5%), *Serratia marcescens* (*n* = 2, 1.5%), *Citrobacter koseri* (*n* = 1, 0.7%) and *Enterobacter aerogenes* (*n* = 1, 0.7%). Blood (*n* = 35, 20.8%), urine (*n* = 29, 17.3%) and tracheal secretion (*n* = 22, 13.1%) were the common specimens that included in this study (Table 1).

Demographic and clinical characteristic of patients

A total of 168 CRE from 168 patients was included in the study; however, 27 patients were excluded from statistical analysis as the data was incomplete in the system. For the 141 sets of patient data extracted from the system, no significant differences in age, races and gender were detected between survivors and non-survivors (Table 2). The mean age of the patients was 54.93 ± 21.42. Chinese were the predominant race (*n* = 52, 36.9%) followed by Malays (*n* = 47, 33.3%), Indians (*n* = 33, 23.4%) and others (*n* = 9, 6.4%). There were 91 male and 50 female patients. The average length of hospitalisation of patients was more than a month which was 41.15 ± 30.74 days. The survivors recorded a longer duration of hospitalisation. From the 141 CRE isolated, 53.2% (*n* = 75) were associated with infection while 46.8% (*n* = 66) were colonisers. The all-cause mortality among patients with CRE isolation (infection/colonisation) was 39.7% (*n* = 56). Additionally, the duration of CRE isolation and appropriate therapy of more than 3 days was statistically associated with higher mortality.

Distribution of carbapenemase genes among CRE strains

The dominant carbapenemase gene detected among the 2014 strains was *blaNDM* (*n* = 19, 55.9%) followed by *blaOXA-48* (*n* = 11, 32.4%). In 2015, *blaOXA-48* (*n* = 103, 76.9%) was the predominant carbapenemase gene among the CRE strains, followed by *blaNDM* (*n* = 53, 39.6%), *blaOXA-232* (*n* = 3, 2.2%) and *blaVIM* (*n* = 1, 0.7%) (Table 1). Both *blaIMP* and *blaKPC* were not detected and 18 strains did not harbour any targeted carbapenemase genes. In 2014, 28 (82.4%) strains harboured single carbapenemase gene and one (2.9%) strain harboured dual carbapenemase genes (*blaOXA-48+blaNDM*). While in 2015, 82 (61.2%) strains harboured single carbapenemase gene and 39 (29.1%) strains harboured dual carbapenemase genes (1 strain with *blaOXA-232+blaVIM*, 38 strains with *blaOXA-48+blaNDM*).
| Table 1 Comparison between CRE samples type, identified CRE species and carbapenemase genes detected in 2014 and 2015. | 2014 (n =) | 2015 (n =) |
|---|---|---|
| **Patient samples** | | |
| Blood | 5 | 30 |
| Urine | 8 | 21 |
| Tracheal secretion | 5 | 17 |
| Sputum | 2 | 13 |
| Bronchoalveolar fluid | 3 | 4 |
| Pleural fluid | 1 | 0 |
| Pus | 1 | 0 |
| Nasopharyngeal secretion | 1 | 2 |
| Respiratory secretion | 0 | 1 |
| Swab | 0 | 5 |
| Peritoneal fluid swab | 1 | 3 |
| Peritoneal slough swab | 1 | 0 |
| Bone swab | 0 | 2 |
| Backbone suction swab | 0 | 2 |
| Cerebrospinal fluid swab | 0 | 1 |
| Bile swab | 0 | 1 |
| Abdomen fluid swab | 0 | 1 |
| Cyst swab | 0 | 1 |
| Fluid swab | 0 | 1 |
| Sacral swab | 1 | 2 |
| Groin swab | 1 | 1 |
| Stoma swab | 1 | 0 |
| Tissue swab | 0 | 6 |
| Wound swab | 2 | 7 |
| Breast swab | 0 | 1 |
| Pus swab | 0 | 5 |
| Ear swab | 0 | 1 |
| Rectal swab | 1 | 1 |
| Tip swab | 0 | 0 |
| Pigtail aspirate swab | 0 | 1 |
| Chest tube swab | 0 | 1 |
| Catheter swab | 0 | 1 |
| Latex A fluid swab | 0 | 1 |
| Eye swab | 0 | 1 |
| **Identified species** | | |
| *Klebsiella pneumoniae* | 25 | 115 |
| *Escherichia coli* | 1 | 11 |
| *Enterobacter cloacae* | 4 | 2 |
| *Serratia marcescens* | 0 | 2 |
| *Citrobacter freundii* | 2 | 2 |
Differential sensitivity to carbapenem/colistin among the CRE clinical strains

A high prevalent of resistant to imipenem and meropenem was detected (Table 3). Based on the CLSI guidelines, majority of the strains were either intermediate or resistant to imipenem (82.2%) and meropenem (74.4%). A total of 14 (8.3%) CRE strains exhibited MIC ≤ 1 for both imipenem and meropenem but were mono-resistant/intermediate to ertapenem. Among these 14 strains, 10 strains (71.4%) were *K. pneumoniae*, 2 strains (14.3%) were *E. coli* and 1 strain (7.1%) each was *Enterobacter cloacae* and *Citrobacter freundii* respectively. In addition, 11 (6.5%) strains were colistin-resistant. Among these 11 strains, 10 strains (90.9%) were *K. pneumoniae* and 1 strain (9.1%) was *Serratia marcescens* (Table 3).

Detection of porin genes associated within *Klebsiella spp.*

Of the 27 *Klebsiella spp.* isolated in 2014, nine strains (33%) loss either 1 or 2 porin(s). The number of strains with at least 1 porin loss reduced in 2015 (*n* = 23; 20%), but 2 strains loss all 3 porins (Table 1).

Molecular characterization of CRKp by PFGE

Based on dendrogram (S1–S3), the 140 CRKp strains were separated into seven major clusters (Cluster I, II, III, IV, V, VI, VII). More than half of the CRKp strains (*n* = 81, 57.6%) were clustered into Cluster I (11 pulsotypes) followed by Cluster IV (*n* = 8, 5.7%) and V (*n* = 7, 5.0%). A total of 48 pulsotypes (*Xba*I1–*Xba*I48) have been generated from the PFGE analysis. Among the detected pulsotypes, pulsotype *Xba*I4, which belonged to Cluster I is the predominant pulsotype that consists of 62 strains (44.3%) which is 100% clonally similar to each other. This pulsotype has been sporadically isolated in January.
| Variables                                           | Survivors (n = 85) | Non-survivors (56) | P value |
|-----------------------------------------------------|--------------------|--------------------|---------|
| Age (years)                                         | 54.21 ± 21.99      | 56.02 ± 20.67      | 0.610<sup>b</sup> |
| Ethnicity                                           |                    |                    |         |
| Malay                                               | 28                 | 19                 | 0.903   |
| Chinese                                             | 32                 | 20                 | 0.816   |
| Indian                                              | 19                 | 14                 | 0.716   |
| Other                                               | 6                  | 3                  | 1.000<sup>a</sup> |
| Gender                                              |                    |                    |         |
| Male                                                | 60                 | 31                 | 0.064   |
| Female                                              | 25                 | 25                 | 0.064   |
| Length of hospitalisation (days)                    | 44.98 ± 31.75      | 35.34 ± 28.45      | 0.035<sup>b</sup> |
| Underlying disorder                                 |                    |                    |         |
| Diabetes mellitus                                   | 25                 | 21                 | 0.316   |
| Hypertension                                        | 32                 | 28                 | 0.147   |
| End-stage renal disease/kidney disease              | 11                 | 21                 | 0.000   |
| Malignancy                                          | 13                 | 12                 | 0.501   |
| Respiratory disease                                 | 3                  | 3                  | 1.000<sup>a</sup> |
| Brain disease                                       | 7                  | 4                  | 1.000<sup>a</sup> |
| Endocrine/metabolite disease                        | 11                 | 4                  | 0.275   |
| Urinary/bladder disease                             | 4                  | 0                  | 0.152<sup>a</sup> |
| Gastrointestinal disease                            | 8                  | 4                  | 0.763<sup>a</sup> |
| Bone/joint disease                                  | 3                  | 3                  | 0.682<sup>a</sup> |
| Skin disease                                        | 9                  | 3                  | 0.363<sup>a</sup> |
| Polytrauma                                          | 5                  | 2                  | 0.703<sup>a</sup> |
| Liver/pancreas disease                              | 8                  | 5                  | 0.923   |
| Tissue disease                                      | 3                  | 0                  | 0.277<sup>a</sup> |
| Blood disorder                                      | 4                  | 7                  | 0.114<sup>a</sup> |
| Neurological disease                                | 4                  | 6                  | 0.195<sup>a</sup> |
| Heart disease                                       | 5                  | 5                  | 0.518<sup>a</sup> |
| Pleural effusion                                    | 2                  | 1                  | 0.518<sup>a</sup> |
| Bowel dislocation                                   | 1                  | 0                  | 1.000<sup>a</sup> |
| Rectal prolapse                                     | 1                  | 0                  | 1.000<sup>a</sup> |
| Infection                                           | 34                 | 28                 | 0.242   |
| Prostate disease                                    | 1                  | 1                  | 1.000<sup>a</sup> |
| Immune disease                                      | 0                  | 1                  | 0.397<sup>a</sup> |
| Parotitis                                           | 0                  | 1                  | 0.397<sup>a</sup> |
| None                                                | 5                  | 0                  | 0.157<sup>a</sup> |
| Invasive device/procedure                           | 81 (95.3%)          | 56 (100%)          | 0.152<sup>a</sup> |
| ICU stay                                            | 50 (58.8%)          | 37 (66.1%)         | 0.479<sup>a</sup> |
| Colonisation/infection                              |                    |                    |         |
| Colonisation                                        | 52 (61.2%)          | 14 (25.0%)         | 0.000   |
| Infection                                           | 33 (38.8%)          | 42 (75.0%)         | 0.000   |

Kong et al. (2022), *PeerJ*, DOI 10.7717/peerj.12830
### Table 2 (continued)

| Variables                                                   | Survivors (n = 85) | Non-survivors (56) | P value |
|--------------------------------------------------------------|--------------------|--------------------|--------|
| Period between isolation and appropriate therapy for infection cases (n = 75) |                    |                    | 0.048  |
| ≤3                                                           | 15                 | 10                 |        |
| >3                                                           | 18                 | 32                 |        |
| Carbenapenemase                                              |                    |                    |        |
| OXA-48                                                       | 38 (44.7%)         | 24 (42.9%)         | 0.829  |
| NDM                                                          | 16 (18.8%)         | 11 (19.6%)         | 0.904  |
| OXA-232                                                      | 1 (1.2%)           | 1 (1.8%)           | 1.000^a|
| OXA-48+NDM                                                   | 18 (21.2%)         | 16 (28.6%)         | 0.315  |
| No genes                                                     | 12 (14.1%)         | 4 (7.1%)           | 0.201  |

Note: P values were obtained using chi-square test unless stated otherwise. P-values^a was obtained using Fishers' exact test. P-values^b was obtained using Mann Whitney U test.

### Table 3 Sensitivity to imipenem, meropenem and colistin among CRE strains.

|                          | Sensitive (≤1 µg/mL) (n =) | Intermediate (2 µg/mL) (n =) | Resistant (≥4 µg/mL) (n =) |
|--------------------------|-----------------------------|-------------------------------|-----------------------------|
| **Imipenem**             |                             |                               |                             |
| *Klebsiella pneumoniae*  | 25                          | 19                            | 96                          |
| *Escherichia coli*       | 2                           | 5                             | 5                           |
| *Enterobacter cloacae*   | 2                           | 2                             | 2                           |
| *Serratia marcescens*    | 0                           | 0                             | 2                           |
| *Citrobacter freundii*   | 1                           | 1                             | 2                           |
| *Escherichia coli*       | 0                           | 0                             | 1                           |
| *Citrobacter koseri*     | 0                           | 0                             | 0                           |
| *Klebsiella oxytoca*     | 0                           | 1                             | 1                           |
| *Enterobacter aerogenes* | 0                           | 0                             | 1                           |
| **Meropenem**            |                             |                               |                             |
| *Klebsiella pneumoniae*  | 30                          | 18                            | 92                          |
| *Escherichia coli*       | 7                           | 1                             | 4                           |
| *Enterobacter cloacae*   | 2                           | 1                             | 3                           |
| *Serratia marcescens*    | 1                           | 0                             | 1                           |
| *Citrobacter freundii*   | 2                           | 1                             | 1                           |
| *Citrobacter koseri*     | 0                           | 0                             | 1                           |
| *Klebsiella oxytoca*     | 1                           | 0                             | 1                           |
| *Enterobacter aerogenes* | 0                           | 1                             | 0                           |

**Sensitive (≤2 µg/mL) (n =)**

**Resistant (>2 µg/mL) (n =)**
Figure 1 The occurrence of pulsotype XbaI4 among CRKp strains from 2014 to 2015. Sporadic isolation of pulsotype XbaI4 was observed in the first two quarters of 2014. However, there was a steep increment in the isolation of this pulsotype from Q4 2014 to Q1 2015. A gradual decrement in the isolation of pulsotype XbaI4 has been observed from Q2 of 2015.

K. pneumoniae is a human commensal that colonises the mucosal surfaces such as gastrointestinal tract and respiratory tract (Podschun & Ullmann, 1998). Gastrointestinal tract has been reported as the important reservoir for the transmission and infection of resistant pathogens (Dorman & Short, 2017). The injudicious use of antibiotics has accelerated the development of antibiotic resistance. Over the years, there has been an increase of cases caused by multidrug-resistant K. pneumoniae and the trends of K. pneumoniae strains harbouring resistance genes such as extended spectrum β-lactamase (ESBL) and carbapenemase genes have also been observed (Müller-Schulte et al., 2020; Sirot et al., 1988; Nordmann, Cuzon & Naas, 2009). The propensity for colonisation, transmission, and survival under selection pressure of antibiotics could have enhanced their survival rate, thus contributing to the high infection rate in the hospital setting.

The surveillance of the major carbapenemase genes such as blaKPC, blaNDM, blaVIM, blaIMP and blaOXA has been carried out in many countries (Hamzan et al., 2015; Rimrang et al., 2012; Hoang et al., 2013; Karuniawati, Saharman & Lestari, 2013). The reported dominant carbapenemase gene in Singapore and China were blaNDM and blaKPC respectively (Teo et al., 2014; Zhang et al., 2017). However, in our study,
blaOXA-48 and blaNDM were the two main carbapenemase genes detected. blaOXA-48 and blaNDM carried on IncI group plasmid and IncFIIK plasmid have been reported. These plasmids have been associated with low fitness burden, high plasmid stability and high transconjugation frequency (Chaalal et al., 2021). In addition, close genetic association between the bleMBL and blaNDM-1 genes has been reported. These two genes are controlled by the same promoter, and this will lead to constitutive expression of blaNDM and bleMBL that encodes a bleomycin resistant protein (BRP). BRF is a functional protein that prevent DNA damage, thus stabilise the plasmid-borne blaNDM. Studies have shown that blaBRF present in both non-clinical and clinical environment. In clinical environment, the medical use of bleomycin as an anticancer agent, contribute to selective pressure that led to further spread of blaNDM in the environment (Dortet, Nordmann & Poirel, 2012). Finally, the dissemination of carbapenemase genes is possibly affected by characteristics of the primary reservoir (which depends on population density, hygiene level, antibiotic selection pressure in that specific area) and population exchange (imported cases from endemic areas) (Nordmann & Poirel, 2014).

Several carbapenem resistance mechanisms could be used among the strains without carbapenemase genes. For this group of strains, the resistance could be attributed by permeability defect (porin loss or mutation) coupled with combination of AmpC expression; or ESBL expression; or non-targeted carbapenemase genes in this study (Crowley, Benedi & Doménech-Sánchez, 2002; Shin et al., 2012; García-Fernández et al., 2010). On the other hand, ertapenem mono resistant non-carbapenemase producing K. pneumoniae (EMRNCP-K.p) is also believed to acquire ESBL genes and/or alteration of porins (Chung, Yong & Lee, 2016). In our present study, only a small number of strains showed the loss of porins that could possibly changes the outer membrane permeability. These group of strains were believed to survive poorly compared to other strains. Previous studies had shown that carbapenem resistant bacteria without porins are usually unstable, thus conferred lower fitness, growth and transmission ability in the hospital environment (Nordmann, Dortet & Poirel, 2012). However, it is noteworthy that the presence of porin associated genes may not guarantee the expression. Expression of porin can also be disrupted by insertional inactivation that alters translation resulting in early termination of translation (Chung, Yong & Lee, 2016; Kaczmarek et al., 2006).

Majority of the CRKp strains co-harbouring blaNDM and blaOXA-48 belonged to Cluster I. On the other hand, 1 strain that did not harbour any targeted carbapenemase genes also grouped in Cluster I. Hence, it is suggested that strains that shared the same genetic backbone might not utilising the same resistance mechanisms.

Although carbapenemase plays an important role in carbapenem resistance, but carbapenemase did not affect the mortality of patients with CRE infection based on statistical analysis. This agrees with previous studies (Daikos et al., 2009). However, there are studies reported the correlations between mortality and severity of underlying diseases as well as the degree of carbapenem resistance (based on MIC value) (Daikos et al., 2009; Daikos et al., 2014). In our study, patients who received definitive treatment at more than 3 days from sample isolation date was significantly associated with mortality compared to patients that received definitive treatment at less or equal than 3 days from
sample isolation date. The rapid initiation of appropriate therapy (definitive treatment) has previously been shown to affect in-hospital mortality, but highly dependent on rapid diagnostic that produce accurate and reliable results (Deresinski, 2007; Kumar et al., 2006). In addition, previous studies also suggested the importance of active screening of patients colonised with carbapenemase-producing CRE for implementation of infection control measures, such as isolation, precautions during invasive procedures, patient transport and environment disinfection (Banerjee & Humphries, 2017).

Based on the comparison of the finding reported by Low et al. (2017) with our current study, the trend of carbapenem-resistance mechanisms has been changed from year 2013 to 2015. Overall, more resistance mechanisms have been observed in year 2013 compared to 2014 and 2015. For instance, blaKPC-2 and blaIMP have been observed in 2013 but not detected in the latter years. The previous study found that CRKp strains with blaKPC in 2013 were associated with Tn4401b transposon (Low et al., 2017). This isoform has been reported to exhibit lower resistance towards carbapenems when compared to other isoforms (Kitchel et al., 2010). Further, these strains did not belong to the high-risk clones that are responsible for the spread of KPC-harbouring K. pneumoniae such as ST258 and ST11 (Lee et al., 2016), hence it only appeared sporadically. On the other hand, in 2013, only 1 strain co-harbouring blaNDM and blaIMP-8 were found but blaNDM has been the main resistance mechanisms among the strains in 2014 although superseded by blaOXA-48 in 2015. Moreover, the increase of strains that did not harbour the five targeted carbapenemase genes has been observed since 2014. In addition, only blaOXA-48 variant was detected among the strains in 2013 and 2014 but in 2015, 3 blaOXA-232 variants were observed. To date, only 2 blaOXA variants (blaOXA-48, blaOXA-181) have been reported in Malaysia (Lau et al., 2021; Lau et al., 2020). This study shed some lights on the changes of main carbapenem-resistance mechanisms in the hospital within the 3-year period; however, further study is required with more recent patient data set to track the genetic shift of these clinical bacterial strains.

The in-hospital mortality rate of CRKp in 2013, 2014 and 2015 were 35.3%, 27.3% and 42.6% respectively. When comparing the CRKp strains among the predominant pulsotype, the in-hospital mortality is increasing from 2013 to 2015 in which the mortality rate of 2013, 2014 and 2015 were 11.1%, 16.7% and 69.6% respectively. The reason behind of the increment could not be concluded based on the collected details. A further study which includes host factors such as white blood cells and nutritional status as well as bacterial virulence factors are needed.

**CONCLUSIONS**

Emergence of CRE was observed in our study setting from 2014 to 2015. The predominant species was K. pneumoniae. The genotypic characterisation of CRKp revealed that the predominant pulsotype had circulated in our setting since 2013. The circulation of this pulsotype with more than one carbapenemase gene could have a negative impact on the management of patients. Hence, this study is important to provide better understanding on the spread of CRE and carbapenemase gene.
ACKNOWLEDGEMENTS
The authors would like to thank University of Malaya and UMMC for facilities and utilities.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding
This research is funded by the Ministry of Higher Education (Malaysia), Fundamental Research Grant Scheme (No: FRGS/1/2018/SKK11/UM/02/4) and the International Society of Infectious Diseases (No. IF016-2015). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
Fundamental Research Grant Scheme: FRGS/1/2018/SKK11/UM/02/4.
International Society of Infectious Diseases: IF016-2015.

Competing Interests
The authors declare that they have no competing interests.

Author Contributions
- Zhi Xian Kong performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
- Rina N. Karunakaran conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.
- Kartini Abdul Jabar conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.
- Sasheela Ponnampalavanar conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.
- Chun Wie Chong conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.
- Cindy Shuan Ju Teh conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.

Ethics
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

The University of Malaya Medical Centre Medical Research Ethics Committee granted Ethical approval to carry out the study within its facilities (20154-1249). The retrospectively collection of patients’ data was granted and did not need the informed consent from patient.
Data Availability

The following information was supplied regarding data availability:

The raw gel pattern, sample isolation date, sample isolation ward, presence of carbapenemase and porins are presented in dendrograms are available in the Supplemental Files.

Supplemental Information

Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.12830#supplemental-information.

REFERENCES

American Thoracic Society and Infectious Diseases Society of America. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. American Journal of Respiratory Critical Care Medicine 171(4):388–416 DOI 10.1164/rccm.200405-644ST.

Banerjee R, Humphries R. 2017. Clinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae. Virulence 8(4):427–439 DOI 10.1080/21505594.2016.1185577.

Chaalal N, Touati A, Bakour S, Aissa MA, Sotto A, Lavigne J-P, Pantel A. 2021. Spread of OXA-48 and NDM-1-producing Klebsiella pneumoniae ST48 and ST101 in chicken meat in western Algeria. Microbial Drug Resistance 27(4):492–500 DOI 10.1089/mdr.2019.0419.

Chung H-S, Yong D, Lee M. 2016. Mechanisms of ertapenem resistance in Enterobacteriaceae isolates in a tertiary university hospital. Journal of Investigative Medicine 64(5):1042–1049 DOI 10.1136/jim-2016-000117.

Clinical and Laboratory Standards Institute (CLSI). 2021. M100 ED31: performance standards for antimicrobial susceptibility testing. 31st Edition. Wayne: Clinical and Laboratory Standards Institute.

Cousins S, Blencowe NS, Blazeby JM. 2019. What is an invasive procedure? A definition to inform study design, evidence synthesis and research tracking. BMJ Open 9(7):e028576 DOI 10.1136/bmjopen-2018-028576.

Crowley B, Benedí VJ, Doménech-Sánchez A. 2002. Expression of SHV-2 β-lactamase and of reduced amounts of OmpK36 porin in Klebsiella pneumoniae results in increased resistance to cephalosporins and carbapenems. Antimicrobial Agents Chemotherapy 46(11):3679–3682 DOI 10.1128/AAC.46.11.3679-3682.2002.

Daikos GL, Petrikkos P, Psychogiou M, Kosmidis C, Vryonis E, Skoutelis A, Georgousi K, Tzouvelekis LS, Tassios PT, Bamia C. 2009. Prospective observational study of the impact of VIM-1 metallo-β-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrobial Agents Chemotherapy 53(5):1868–1873 DOI 10.1128/AAC.00782-08.

Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psychogiou M, Argyropoulou A, Stefanou I, Syspa V, Miriagou V, Nepka M. 2014. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrobial Agents Chemotherapy 58(4):2322–2328 DOI 10.1128/AAC.02166-13.

David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, Abudahab K, Goater R, Giani T, Errico G. 2019. Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is...
References:

Deresinski S. 2007. Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data. *Clinical Infectious Diseases* 45(Supplement_3):S177–S183 DOI 10.1086/519472.

Dhainaut J-F, Claessens Y-E, Janes J, Nelson DR. 2005. Underlying disorders and their impact on the host response to infection. *Clinical Infectious Diseases* 41(Supplement_7):S481–S489 DOI 10.1086/432001.

Dorman MJ, Short FL. 2017. Genome watch: Klebsiella pneumoniae: when a colonizer turns bad. *Nature Reviews Microbiology* 15(7):384–385 DOI 10.1038/nrmicro.2017.64.

Dortet L, Nordmann P, Poirel L. 2012. Association of the emerging carbapenemase NDM-1 with a bleomycin resistance protein in Enterobacteriaceae and Acinetobacter baumannii. *Antimicrobial Agents Chemotherapy* 56(4):1693–1697 DOI 10.1128/AAC.05583-11.

European Centre for Disease Prevention and Control. 2020. Carbapenem-resistant Enterobacteriaceae. Available at [http://ecdc.europa.eu/en/publications/publications/carbapenem-resistant-enterobacteriaceae-risk-assessment-april-2016.pdf](http://ecdc.europa.eu/en/publications/publications/carbapenem-resistant-enterobacteriaceae-risk-assessment-april-2016.pdf) (accessed 25 March 2020).

Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL. 2002. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. *Annals of Internal Medicine* 137(10):791–797 DOI 10.7326/0003-4819-137-10-200211190-00007.

García-Fernández A, Miriagou V, Papagiannitsis CC, Giordano A, Venditti M, Mancini C, Carattoli A. 2010. An ertapenem-resistant extended-spectrum-β-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. *Antimicrobial Agents Chemotherapy* 54(10):4178–4184 DOI 10.1128/AAC.01301-09.

Girmenia C, Rossolini G, Picciocchi A, Bertaina A, Pisapia G, Pastore D, Sica S, Severino A, Cudillo L, Ciceri F. 2015. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. *Bone Marrow Transplantation* 50(2):282–288 DOI 10.1038/bmt.2014.231.

Hamzan NI, Yean CY, Rahman RA, Hasan H, Rahman ZA. 2015. Detection of bla IMP4 and bla NDM1 harboring Klebsiella pneumoniae isolates in a university hospital in Malaysia. *Emerging Health Threats Journal* 8(1):2601 DOI 10.3402/ehjt.v8.26011.

Hoang TH, Wertheim H, Minh NB, Duong TN, Anh DD, Phuong TTL, Son TH, Izumiya H, Ohnishi M, Shibayama K. 2013. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains containing New Delhi metallo-beta-lactamase isolated from two patients in Vietnam. *Journal of Clinical Microbiology* 51(1):373–374 DOI 10.1128/JCM.02322-12.

Institute for Medical Research. 2020. National surveillance of antimicrobial resistance, Malaysia. Available at [https://www.imr.gov.my/en/component/content/article/75-english-content/national-collaboration/1469-nsar-main.html](https://www.imr.gov.my/en/component/content/article/75-english-content/national-collaboration/1469-nsar-main.html) (accessed 25 March 2020).

Kaczmarek FM, Dib-Hajj F, Shang W, Gootz TD. 2006. High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla ACT-1 β-lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin PhoE. *Antimicrobial Agents Chemotherapy* 50(10):3396–3406 DOI 10.1128/AAC.00285-06.

Karuniawati A, Saharman YR, Lestari DC. 2013. Detection of carbapenemase encoding genes in Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii isolated from patients at Intensive Care Unit Cipto Mangunkusumo Hospital in 2011. *Acta Medica Indonesiana* 45:101–106.
Kitchel B, Rasheed JK, Endimiani A, Hujer AM, Anderson KF, Bonomo RA, Patel JB. 2010. Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae. *Antimicrobial Agents Chemotherapy* 54(10):4201–4207 DOI 10.1128/AAC.00008-10.

Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L. 2006. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. *Critical Care Medicine* 34(6):1589–1596 DOI 10.1097/01.CCM.0000217961.75225.E9.

Lau MY, Ponnampalavanar S, Lee WS, Jabar KA, Chua KH, Idris N, Chong CW, Yap PSX, Teh CSJ. 2020. First detection of Klebsiella quasipneumoniae producing OXA-181 carbapenemase in Malaysia. *Journal of Infection Chemotherapy* 26(10):1058–1061 DOI 10.1016/j.jiac.2020.05.009.

Lau MY, Teng FE, Chua KH, Ponnampalavanar S, Chong CW, Abdul Jabar K, Teh CSJ. 2021. Molecular characterization of carbapenem resistant Klebsiella pneumoniae in Malaysia Hospital. *Pathogens* 10(3):279 DOI 10.3390/pathogens10030279.

Lee CR, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. 2016. Global dissemination of carbapenemase-producing Klebsiella pneumoniae: epidemiology, genetic context, treatment options, and detection methods. *Frontiers in Microbiology* 7:895 DOI 10.3389/fmicb.2016.00895.

Lim KT, Teh CSJ, Thong KL. 2013. Loop-mediated isothermal amplification assay for the rapid detection of Staphylococcus aureus. *BioMed Research International* 2013(2):1–5 DOI 10.1155/2013/895816.

Ling ML, Tee YM, Tan SG, Amin IM, How KB, Tan KY, Lee LC. 2015. Risk factors for acquisition of carbapenem resistant Enterobacteriaceae in an acute tertiary care hospital in Singapore. *Antimicrobial Resistance Infection Control* 4(1):1–7 DOI 10.1186/s13756-015-0066-3.

Low Y-M, Yap PS-X, Jabar KA, Ponnampalavanar S, Karunakaran R, Velayuthan R, Chong C-W, Bakar SA, Yusof MYM, Teh CS-J. 2017. The emergence of carbapenem resistant Klebsiella pneumoniae in Malaysia: correlation between microbiological trends with host characteristics and clinical factors. *Antimicrobial Resistance Infection Control* 6(1):1–13 DOI 10.1186/s13756-016-0164-x.

Malchione MD, Torres LM, Hartley DM, Koch M, Goodman JL. 2019. Carbapenem and colistin resistance in Enterobacteriaceae in Southeast Asia: review and mapping of emerging and overlapping challenges. *International Journal of Antimicrobial Agents* 54(4):381–399 DOI 10.1016/j.ijantimicag.2019.07.019.

Müller-Schulte E, Tuo MN, Akoua-Koffi C, Schaumburg F, Becker SL. 2020. High prevalence of ESBL-producing Klebsiella pneumoniae in clinical samples from central Côte d’Ivoire. *International Journal of Infectious Diseases* 91:207–209 DOI 10.1016/j.ijid.2019.11.024.

Naas T, Cuzon G, Villegas M-V, Lartigue M-F, Quinn JP, Nordmann P. 2008. Genetic structures at the origin of acquisition of the β-lactamase bla KPC gene. *Antimicrobial Agents Chemotherapy* 52(4):1257–1263 DOI 10.1128/AAC.01451-07.

Nordmann P, Cuzon G, Naas T. 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. *The Lancet Infectious Diseases* 9(4):228–236 DOI 10.1016/S1473-3099(09)70054-4.

Nordmann P, Dortet L, Poirel L. 2012. Carbapenem resistance in Enterobacteriaceae: here is the storm!. *Trends in Molecular Medicine* 18(5):263–272 DOI 10.1016/j.molmed.2012.03.003.
Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemase-producing Enterobacteriaceae. Emerging Infectious Diseases 17(10):1791–1798 DOI 10.3201/eid1710.110655.

Nordmann P, Poirel L. 2014. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clinical Microbiology Infection 20(9):821–830 DOI 10.1111/1469-0691.12719.

Paterson DL, Ko W-C, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA. 2004. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clinical Infectious Diseases 39(1):31–37 DOI 10.1086/420816.

Pitout JD, Nordmann P, Poirel L. 2015. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrobial Agents Chemotherapy 59(10):5873–5884 DOI 10.1128/AAC.01019-15.

Podschun R, Ullmann U. 1998. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clinical Microbiology Reviews 11(4):589–603 DOI 10.1128/CMR.11.4.589.

Poirel L, Héritier C, Tolün V, Nordmann P. 2004. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrobial Agents Chemotherapy 48(1):15–22 DOI 10.1128/AAC.48.1.15-22.2004.

Poirel L, Walsh TR, Cuvillier V, Nordmann P. 2011. Multiplex PCR for detection of acquired carbapenemase genes. Diagnostic Microbiology Infectious Disease 70(1):119–123 DOI 10.1016/j.diagmicrobio.2010.12.002.

Rahal JJ. 2008. The role of carbapenems in initial therapy for serious Gram-negative infections. Critical Care 12(Suppl 4):1–7 DOI 10.1186/cc6821.

Rimrang B, Chanawong A, Lulitanond A, Wilailuckana C, Charoensri N, Sribenjalux P, Phumsrikaew W, Wonglakorn L, Kerdsin A, Chetchotisakd P. 2012. Emergence of NDM-1- and IMP-14a-producing Enterobacteriaceae in Thailand. Journal of Antimicrobial Chemotherapy 67(11):2626–2630 DOI 10.1093/jac/dks267.

Shin SY, Bae IK, Kim J, Jeong SH, Yong D, Kim JM, Lee K. 2012. Resistance to carbapenems in sequence type 11 Klebsiella pneumoniae is related to DHA-1 and loss of OmpK35 and/or OmpK36. Journal of Medical Microbiology 61(2):239–245 DOI 10.1099/jmm.0.037036-0.

Sirot J, Chanal C, Petit A, Sirot D, Labia R, Gerbaud G. 1988. Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated β-lactamases markedly active against third-generation cephalosporins: epidemiologic studies. Clinical Infectious Diseases 10(4):850–859 DOI 10.1093/clinids/10.4.850.

Slama TG. 2008. Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use. Critical Care 12(5):1–10 DOI 10.1186/cc6994.

Teo JW, Tan P, La M-V, Krishnan P, Tee N, Koh TH, Deepak RN, Tan TY, Jureen R, Lin RT. 2014. Surveillance trends of carbapenem-resistant Enterobacteriaceae from Singapore, 2010–2013. Journal of Global Antimicrobial Resistance 2(2):99–102 DOI 10.1016/j.jgar.2013.11.003.

Thaden JT, Lewis SS, Hazen KC, Hulslage K, Fowler VG, Moehring RW, Chen LF, Jones CD, Moore ZS, Sexton DJ. 2014. Rising rates of carbapenem-resistant enterobacteriaceae in community hospitals: a mixed-methods review of epidemiology and microbiology practices in a network of community hospitals in the southeastern United States. Infection Control Hospital Epidemiology 35(8):978–983 DOI 10.1086/677157.
Thaden JT, Lewis SS, Hazen KC, Huslage K, Fowler VG, Moehring RW, Chen LF, Jones CD, Moore ZS, Sexton DJ. 2014. Rising rates of carbapenem-resistant enterobacteriaceae in community hospitals: a mixed-methods review of epidemiology and microbiology practices in a network of community hospitals in the southeastern United States. *Infection Control Hospital Epidemiology* 35(8):978–983 DOI 10.1086/677157.

The European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2021. Breakpoint tables for interpretation of MICs and zone diameters. 2021. Version 6.0, 2016. Available at [http://www.eucast.org/clinical_breakpoints/](http://www.eucast.org/clinical_breakpoints/) (accessed 25 March 2021).

Wang Q, Zhang Y, Yao X, Xian H, Liu Y, Li H, Chen H, Wang X, Wang R, Zhao C. 2016. Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections. *European Journal of Clinical Microbiology Infectious Diseases* 35(10):1679–1689 DOI 10.1007/s10096-016-2710-0.

Xu Y, Gu B, Huang M, Liu H, Xu T, Xia W, Wang T. 2015. Epidemiology of carbapenem-resistant Enterobacteriaceae (CRE) during 2000–2012 in Asia. *Journal of Thoracic Disease* 7:376 DOI 10.3978/j.issn.2072-1439.2014.12.33.

Zaidah AR, Mohammad NI, Suraiya S, Harun A. 2017. High burden of Carbapenem-resistant Enterobacteriaceae (CRE) fecal carriage at a teaching hospital: cost-effectiveness of screening in low-resource setting. *Antimicrobial Resistance & Infection Control* 6(1):1–6 DOI 10.1186/s13756-017-0200-5.

Zhang R, Liu L, Zhou H, Chan EW, Li J, Fang Y, Li Y, Liao K, Chen S. 2017. Nationwide surveillance of clinical carbapenem-resistant Enterobacteriaceae (CRE) strains in China. *EBioMedicine* 19(1):98–106 DOI 10.1016/j.ebiom.2017.04.032.